The Middle East and Africa held a 2% share of the market in 2025 and are expected to grow at a notable CAGR of 14.8% during the projection period, driven by expanding healthcare investments and obesity management programs
But once patients start a GLP-1 receptor agonist, they may need to keep taking it indefinitely
According to Brown & Brown's 2025 employer survey, 37% of self-insured employers now cover GLP-1s for weight loss, but nearly 60% impose restrictions like prior authorization and mandatory lifestyle program participation
It means alcohol works against your goal through several mechanisms at once, and the effect adds up over weeks
These medications bind to GLP-1 receptors located throughout the body, including the pancreas, gastrointestinal tract, and importantly, the central nervous system